Filing Details
- Accession Number:
- 0001628280-24-047155
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-12 16:15:18
- Reporting Period:
- 2024-11-11
- Accepted Time:
- 2024-11-12 16:15:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1356576 | Supernus Pharmaceuticals Inc. | SUPN | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1005544 | Iii W Charles Newhall | C/O Supernus Pharmaceuticals, Inc., 9715 Key West Avenue Rockville MD 20850 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-11-11 | 20,000 | $9.13 | 140,975 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-11-11 | 10,700 | $36.24 | 130,275 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Director Stock Option (Right to Buy) | Disposition | 2024-11-11 | 20,000 | $0.00 | 20,000 | $9.13 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2016-03-03 | 2025-03-03 | No | 4 | M | Direct |
Footnotes
- The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.